Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Aditxt ( (ADTX) ) is now available.
On May 1, 2026, Aditxt’s shareholders approved a proposal to authorize a reverse split of the company’s common stock, and the board subsequently set the ratio at 1-for-27. A certificate of amendment was filed in Delaware on May 14, 2026, making the reverse split effective as of 4:01 p.m. Eastern Time on May 15, 2026, with split-adjusted trading on Nasdaq commencing on May 18, 2026 under the existing ADTX ticker.
The move, which reduced Aditxt’s outstanding shares from about 13.8 million to roughly 510,000 while keeping authorized share count and par value unchanged, is primarily aimed at regaining compliance with Nasdaq’s minimum bid price requirement. Proportionate adjustments will be made to outstanding stock options, restricted stock units, warrants, and related exercise prices, with fractional shares rounded up, while shareholders holding in book-entry or through intermediaries are not required to take any action.
The reverse split also results in a new CUSIP (007025869) for Aditxt’s common stock, and the company’s transfer agent will provide stockholders of record with updated ownership information. The restructuring of the capital base could help stabilize Aditxt’s listing status on Nasdaq, a key consideration for existing investors and for the company’s ability to access public capital markets going forward.
More about Aditxt
Aditxt, Inc. is a social innovation platform focused on accelerating promising health innovations through an ecosystem of research institutions, industry partners, and shareholders. The company employs a collaborative model aimed at democratizing innovation, driving disruptive growth, and addressing significant societal challenges in the healthcare sector.
Its platform-centric strategy emphasizes stakeholder participation and collective progress, positioning Aditxt as an intermediary that supports the development and scaling of health-related technologies rather than a traditional single-product biotech. This model is designed to capture value across multiple disciplines and projects within the broader health innovation landscape.
Average Trading Volume: 2,067,684
Technical Sentiment Signal: Strong Sell
Current Market Cap: $60.42K
Find detailed analytics on ADTX stock on TipRanks’ Stock Analysis page.